Skip to main content
. 2021 Jun 18;39(2):113–121. doi: 10.3857/roj.2021.00213

Table 1.

Summary of patient demographics, clinical factors, and treatment variables (n = 12)

Value
Age (yr) 65.5 (56–83)
 <65 5 (42)
 ≥65 7 (58)
Sex
 Male 7 (58)
 Female 5 (42)
Race
 White 5 (42)
 Hispanic 2 (17)
 Asian 5 (42)
Diagnosis
 HCC 9 (75)
 Cholangiocarcinoma 2 (17)
 Neuroendocrine liver metastasis 1 (8)
ECOG performance status
 0 7 (58)
 1 4 (33)
 2 1 (8)
Child–Pugh classification
 A 9 (75)
 B 3 (25)
 C 0 (0)
Location of PVTT
 Segmental branch 2 (17)
 Left/right PV 9 (75)
 Main PV 1 (8)
90Y dose (Gy) 104.3 (83.3–131.7)
90Y volume (mL) 846 (675–1,068)
Five-fraction SBRT dose (Gy) 32.5 (27.5–50)
 <30 3 (25)
 30–35 4 (33)
 40–45 3 (25)
 ≥50 2 (17)
Days between 90Y and SBRT
 <30 1 (8)
 30–60 5 (42)
 60–90 2 (17)
 >90 4 (33)
PTV volume (mL) 91.3 (14.7–623.2)
 <50 2 (17)
 50–100 5 (42)
 100–250 2 (17)
 250–500 2 (17)
 >500 1 (8)
Previous treatments
 Surgical resection 0 (0)
 Liver transplant 0 (0)
 Systemic therapy 0 (0)
Maintenance therapy afterwards
 Yes 7 (58)
 No 5 (42)

Values are presented as median (range) or number (%).

HCC, hepatocellular carcinoma; ECOG, Eastern Cooperative Oncology Group; PVTT, portal vein tumor thrombosis; PV, portal vein; 90Y, yttrium-90; SBRT, stereotactic body radiation therapy; PTV, planning target volume.